Polypharmacy in Heart Failure: Progress But Also Problem - 28/08/21

Doi : 10.1016/j.amjmed.2021.05.007

Parag Goyal, MD, MSc ^a,^⁎ , Sabrina Mangal, PhD, RN ^b, Ashok Krishnaswami, MD MAS ^c, Michael W. Rich, MD ^d
^a Department of General Internal Medicine, Division of Cardiology, Weill Cornell Medicine, New York, NY
^b Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
^c Division of Cardiology, Kaiser Permanente San Jose Medical Center, San Jose, Calif
^d Cardiovascular Division, Washington University School of Medicine, St. Louis, Mo

^⁎Additional corrections: Request for reprints should be addressed to Parag Goyal, MD, MSc, Assistant Professor of Medicine, Department of General Internal Medicine, Division of Cardiology, Weill Cornell Medicine, 420 E 70th Street, New York, NY 10021.Assistant Professor of MedicineDepartment of General Internal MedicineDivision of CardiologyDepartment of MedicineWeill Cornell Medicine420 E 70th StreetNew YorkNY10021

El texto completo de este artículo está disponible en PDF.

	Funding: None.
	Conflicts of Interest: PG is supported by American Heart Association grant 20CDA35310455, National Institute on Aging grant K76AG064428, and Loan Repayment Program award L30AG060521; receives personal fees for medicolegal consulting related to heart failure; and has received honoraria from Akcea Inc and Bionest Inc. SM is supported by the National Institute on Aging grant K76AG064428-01A1.
	Authorship: All authors had access to the data and a role in writing this manuscript.